Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a repurchase of 57,500 H-shares on 8 June 2026, acquiring the stock on the Hong Kong Stock Exchange at prices between HKD 18.96 and HKD 19.57 per share. The transaction totalled HKD 1.10 million based on a volume-weighted average price of HKD 19.18 per share.

Following the repurchase, ZYLOXTB’s outstanding share count (excluding treasury shares) decreased by 0.0173 % to 325.41 million, while treasury shares rose to 10.94 million. The company’s total issued share capital remains at 336.35 million shares.

The buyback forms part of the mandate approved by shareholders on 13 May 2026, which authorises the company to repurchase up to 32.72 million shares. Including the latest transaction, ZYLOXTB has repurchased 1.80 million shares under this mandate, representing 0.54 % of the issued share base at the date the authority was granted.

Under Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 8 July 2026.